Clinical Trials Logo

Neuroendocrine Tumours (NET) clinical trials

View clinical trials related to Neuroendocrine Tumours (NET).

Filter by:
  • None
  • Page 1

NCT ID: NCT04649580 Completed - Clinical trials for Neuroendocrine Tumours (NET)

United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting

PREF-NET
Start date: April 27, 2021
Phase:
Study type: Observational

The aim of the study is to generate real-world evidence to describe the patient experience of administration of Somatuline® Autogel® (lanreotide) in homecare and hospital settings, and the associated impact on healthcare utilisation, societal cost, work productivity and health-related quality of life (HRQoL)

NCT ID: NCT04525638 Recruiting - Clinical trials for Neuroendocrine Tumours (NET)

A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

Start date: June 29, 2020
Phase: Phase 2
Study type: Interventional

This is a prospective, multi-centre, open-label, single-arm, stratified, exploratory, Phase 2 study evaluating the efficacy and safety of 177Lu-DOTATATE in combination with nivolumab in adult patients with Grade 3 neuroendocrine tumours (NET) or neuroendocrine carcinomas (NEC).